Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8976 results

  1. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]

    Awaiting development Reference number: GID-TA11653 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]

    Awaiting development Reference number: GID-TA11691 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]

    Awaiting development Reference number: GID-TA11778 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Ruxolitinib for treating moderate atopic dermatitis [ID6602]

    Awaiting development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]

    Awaiting development Reference number: GID-TA11699 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    Awaiting development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

    In development Reference number: GID-TA11651 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  15. Unilateral and staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-IPG10441 Expected publication date:  17 December 2026

    Interventional procedures guidance
    In development